Radiation therapy for early stage unfavorable Hodgkin lymphoma: Is dose reduction feasible?

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2356-2361

  Laskar, Siddhartha ^a   Kumar, Deepak P ^a   Khanna, Nehal ^a   Menon, Hari ^a   Sengar, Manju ^a   Arora, Brijesh ^a   Gujral, Sumeet ^a   Shet, Tanuja ^a   Sridhar, Epari ^a   Rangarajan, Venkatesh ^a   Muckaden, Mary Ann ^a   Nair, Reena ^a   Banavali, Shripad ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Hodgkin lymphoma; Prognostication; Radiation

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHILD; DRUG EFFICACY; EARLY CANCER; FEASIBILITY STUDY; FEMALE; HISTOLOGY; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION DOSE REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIATION DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925343271     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.871631     Document Type: Article

References (21)

1. Gisselbrecht C, Mounier N, Andre M, et al. How to define intermediate stage in Hodgkin's lymphoma? Eur J Haematol Suppl 2005;(86):11-14.
2. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128-3135.
3. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved field radiation in early stage Hodgkin's disease. N Engl J Med 2007;357:1916-1927.
4. Cosset JM, Henry-Amar M, Meerwaldt JH. Long term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. Ann Oncol 1991;2(Suppl. 2):77-82.
5. Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994;12:297-305.
6. Loeffler M, Brosteau O, Hasenclever D, et al. Meta-analysis of chemotherapy vs. combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Study Group. J Clin Oncol 1998;16:818-829.
7. Ferme C, Eghbali H, Hagenbeek A, et al. MOPP/ABV hybrid and irradiation in unfavourable supra-diaphragmatic clinical stages I-II Hodgkin's disease: comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood 2000;96(Suppl. 1): Abstract 576.
8. Ferme C, Divine M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavourable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial. Blood 2005;106(Suppl. 1): Abstract 813.
9. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol 2010;28:4199-4206.
10. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVDand involved field radiotherapy (IFRT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. J Clin Oncol 2012;30:907-913.
11. Advani R, Hoppe T, Lauren S, et al. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys 2011;81:1374-1379.
12. Ng AK, Bernardo MVP, Weller E, et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-1996.
13. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854-862.
14. Levi JA, Wiernik PH. Limited extranodal Hodgkin's disease. Unfavorable prognosis and therapeutic implications. Am J Med 1977;63:365-372.
15. Leslie NT, Mauch PM, Hellman S. Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency. Cancer 1985;55:2072-2078.
16. Connors JM, Klimo P. Is it an E lesion or stage IV? An unsettled issue in Hodgkin's disease staging. J Clin Oncol 1984;2:1421-1423.
17. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-439.
18. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002;13(Suppl. 1):86-91.
19. Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004;101:1824-1834.
20. Tubiana M, Henry-Amar M, Van Der Werf-Messing, et al. A multivariate analysis of prognostic factors in early Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985;11:23-30.
21. Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: a report from the International Data Base on Hodgkin's Disease. Semin Oncol 1990;17:758-768.